6 Panel Oral Swab Drug Test

What Is a 6 Panel Drug Test and What Does It Screen For?

The 6 panel saliva drug test expands the standard five-substance baseline by adding one critical analyte that changes the scope of what the program can detect and who it serves. At 12 Panel Now, the 6 panel oral swab is available in two configurations. The first covers Amphetamines (AMP), Cocaine (COC), Methamphetamine (MET), Opiates/Morphine (OPI/MOR), Oxycodone (OXY), and Alcohol (ALC) and is built for transportation employers, post-accident investigation programs, and compliance settings where simultaneous drug and alcohol screening in a single observed collection is the operational requirement. The second covers Amphetamines (AMP), Benzodiazepines (BZO), Cocaine (COC), Methamphetamine (MET), Opiates/Morphine (OPI/MOR), and Oxycodone (OXY) and is designed for pain management clinics, healthcare facilities, and treatment programs where benzodiazepine detection alongside opioid screening is a clinical and compliance priority. Neither configuration includes THC, which is an intentional design choice that reflects the specific program populations each configuration serves. Both carry a Forensic Use Only classification and are available for same-day wholesale shipping starting from $1.39 per unit.

Why Is Oxycodone Included in Both 6 Panel Configurations?

Oxycodone appears in both configurations of the 6 panel oral fluid drug test because the prescription opioid crisis has made oxycodone one of the most clinically and operationally significant substances to screen for in any program that already covers heroin and morphine through the OPI strip. The standard OPI/MOR analyte at 40 ng/mL detects heroin, codeine, and morphine but does not detect oxycodone, which requires its own dedicated OXY strip at a 20 ng/mL cutoff. Including OXY in both 6 panel configurations ensures that programs screening at the 6 panel tier have opioid coverage that reflects the current opioid landscape rather than relying on a heroin-focused OPI strip that systematically misses the most commonly diverted prescription opioid in the United States. SAMHSA’s Mandatory Guidelines specifically identify oxycodone and oxymorphone as part of the authorized opioids testing panel for federal workplace programs, reinforcing that oxycodone detection is a recognized federal priority in drug-free workplace programs.

Does a Mouth Swab Drug Test Detect Alcohol?

Yes, in the ALC configuration. The mouth swab alcohol test in the 6 panel ALC variant detects ethanol in oral fluid at a threshold of 0.02%, which corresponds to the legal impairment threshold used in most US workplace and DOT compliance programs under 49 CFR Part 40. The operational advantage of oral fluid alcohol detection over urine-based EtG testing is significant and comes down to a single critical distinction. Urine EtG testing can detect alcohol metabolites for up to 80 hours after consumption, meaning a positive urine EtG result tells an administrator that the donor consumed alcohol at some point in the past three to four days. The oral fluid alcohol strip tells an administrator something far more precise: the donor has alcohol in their system right now or consumed within the past 12 to 24 hours. In a post-accident investigation or a reasonable suspicion check following an on-site incident, the oral fluid result answers the only question that matters — was this person drinking today? For programs operating under DOT’s Office of Drug and Alcohol Policy and Compliance requirements, alcohol testing is a mandated component of the safety-sensitive employee testing program, and the 6 panel oral swab ALC configuration provides that simultaneous drug and alcohol screening capability in a single non-invasive observed collection without the logistical requirements of a separate breath alcohol test device.

How Long Does Alcohol Stay Detectable in a Saliva Drug Test?

Alcohol is detectable in oral fluid for approximately 12 to 24 hours following consumption, depending on the amount consumed, the rate of consumption, the individual’s body weight, and their metabolic rate. This is considerably shorter than the 80-hour EtG window in urine, which makes the oral fluid alcohol test the most accurate format for detecting current or very recent alcohol use rather than consumption from several days prior. For post-accident testing and reasonable suspicion checks, this precision is an advantage rather than a limitation. The relevant legal standard in most safety-sensitive workplace contexts is whether the employee was impaired at the time of the incident, not whether they consumed alcohol at some point during the past week. Oral fluid alcohol detection answers that question directly. For programs that need historical alcohol detection beyond the 24-hour window, urine EtG testing paired with an oral swab panel provides comprehensive coverage across both recent and historical timeframes. The standalone alcohol saliva test at 12 Panel Now is also available as a single-substance device for programs that need alcohol-only screening separate from a multi-drug panel.

Does a 6 Panel Oral Swab Detect Benzodiazepines?

Yes, in the BZO configuration. Benzodiazepines are a class of central nervous system depressants that includes Xanax, Valium, Klonopin, and Ativan, all of which are Schedule IV controlled substances with significant abuse and diversion potential. The BZO strip in the 6 panel mouth swab drug test detects benzodiazepine compounds at a cutoff of 50 ng/mL in oral fluid. Benzodiazepines are absent from all 5 panel oral swab configurations, meaning any program still running a 5 panel that has encountered benzodiazepine misuse in its population is producing false negative results for that substance across every test administered. The clinical and workplace significance of this gap is substantial. Benzodiazepines produce sedation, impaired coordination, slowed reaction time, and cognitive impairment comparable to alcohol intoxication. The CDC reports that benzodiazepines are involved in a significant share of overdose deaths, both alone and in combination with opioids, making their detection a public health as well as a workplace safety priority. For rehabilitation and treatment centers managing patients on medication-assisted treatment programs, benzodiazepine screening alongside opioid detection provides the clinical picture needed to identify co-occurring misuse patterns that a standard 5 panel screen would miss entirely.

How Long Do Benzodiazepines Stay Detectable in a Saliva Drug Test?

Benzodiazepines are generally detectable in oral fluid for up to 72 hours, though this varies significantly by specific compound and dosage. Long-acting benzodiazepines such as diazepam and oxazepam have longer detection windows than shorter-acting compounds like lorazepam, which the body metabolizes faster. This variability means that a single BZO strip result must be interpreted with an understanding that a negative result on a long-acting benzodiazepine user who consumed several days ago may not definitively confirm absence of use. For programs where benzodiazepine monitoring is a sustained clinical requirement rather than a one-time screening event, regular and frequent testing with the BZO configuration of the 6 panel saliva drug test provides a more complete compliance picture than infrequent or scheduled testing alone. Programs that need to distinguish between specific benzodiazepine compounds, such as a treatment center confirming which prescribed benzodiazepine is present and at what concentration, should always pursue laboratory confirmation using LC-MS/MS methodology, which can identify and quantify individual benzodiazepine compounds rather than producing a single class-level screening result.

How the 6 Panel Oral Swab Immunoassay Actually Works

The 6 panel oral swab drug test uses a lateral flow immunoassay, the same detection principle used in rapid diagnostic tests across clinical and point-of-care settings including pregnancy tests, COVID antigen tests, and influenza screens. When the collection swab is saturated with oral fluid and inserted into the device, the sample migrates along the nitrocellulose test strip by capillary action. Each of the six analyte zones on the strip contains antibodies that are specific to one targeted substance. When a substance is present in the oral fluid at or above its cutoff concentration, it saturates the available antibody binding sites and prevents the drug-protein conjugate from forming a visible colored line in that zone, producing a presumptive positive. When the substance is absent or below the cutoff, the antibodies bind to the drug conjugate and form a visible line, confirming a negative result. The control line, which must be visible in every valid result, confirms the immunoassay reagents are functioning correctly. Quest Diagnostics notes that the saturation indicator on oral fluid collection devices is a critical quality control feature that directly reduces the rate of insufficient-volume specimen rejections, which is the most common procedural error in rapid oral fluid screening programs. All results must be read within 5 to 10 minutes of device activation. Results read before the 5-minute mark or after the 10-minute window are not reliable.

Can the 6 Panel Oral Swab Produce a False Positive?

Yes. As with all rapid immunoassay screening devices, the 6 panel oral fluid drug test can produce presumptive positive results driven by cross-reactive compounds rather than the targeted substance itself. This cross-reactivity risk varies by analyte. The amphetamine strip can react to certain prescription stimulants and decongestants. The benzodiazepine strip can react to some non-benzodiazepine sedatives that share structural similarities. The opiate strip can react to poppy seed consumption. The oxycodone strip is generally more specific but can still cross-react with other opioid compounds at high concentrations. This is why every presumptive positive result from a rapid screening device, including the 6 panel mouth swab drug test, must be confirmed by a licensed laboratory using GC-MS or LC-MS/MS before any formal action is taken. The SAMHSA Drug-Free Workplace FAQ states that a Medical Review Officer review is required for all positive results in federally regulated programs before any adverse employment action is taken, specifically because rapid immunoassay screening is designed to be sensitive rather than specific, and false positives from cross-reactive compounds are a recognized and expected limitation of the technology.

Who Uses the 6 Panel Saliva Drug Test and What Do Real Program Scenarios Look Like?

The ALC configuration of the 6 panel oral swab drug test is the right tool for any program that needs to answer two questions simultaneously at the point of an incident or a supervision check: did this person use drugs, and did they consume alcohol? A transportation company conducting a post-accident investigation at a remote job site cannot wait to send the driver to an off-site collection facility. Administering the 6 panel ALC oral swab at the scene gives the safety officer drug and alcohol results in under 10 minutes with a fully observed tamper-resistant collection and no need for a restroom or specimen handling equipment. A probation officer supervising a client whose conditions of release include alcohol abstinence can administer the ALC configuration during a routine check-in and confirm both drug and alcohol compliance in the same collection. The BZO configuration addresses a different scenario entirely. A pain management clinic prescribing opioids to patients needs to verify that patients are not also misusing benzodiazepines, which dramatically increases overdose risk when combined with opioids. The CDC has documented that benzodiazepine and opioid co-use is a primary driver of overdose mortality, making the BZO/OXY combination in the 6 panel BZO configuration a clinically meaningful screening tool for any program managing patients or employees on opioid therapy. A treatment center conducting intake screening can use the BZO configuration to identify incoming patients who are using benzodiazepines alongside other substances, which directly informs the clinical team’s detox and treatment planning before a full laboratory panel is ordered.

When Should a Program Move Up to the 8, 9, or 10 Panel Instead?

The 6 panel covers either alcohol or benzodiazepines as the sixth analyte. If the program needs both alcohol and benzodiazepines in a single device, neither 6 panel configuration provides that combination. The 9 panel oral swab includes both alcohol and benzodiazepines alongside methadone and the standard baseline substances, making it the appropriate tier for methadone maintenance programs needing comprehensive monitoring in a single device. The 8 panel oral swab adds barbiturates and buprenorphine coverage to the benzodiazepine and opioid baseline, making it the right choice for Suboxone clinics and MAT programs that need to monitor buprenorphine compliance alongside illicit substance use. Programs that need fentanyl detection must select a configuration that includes a dedicated FEN strip. Fentanyl is a synthetic opioid that does not cross-react with the standard OPI strip and is not available at the 6 panel tier. The 7 panel FEN/K2/ALC variant is the entry-level configuration for fentanyl detection in oral fluid at 12 Panel Now, and broader fentanyl coverage is available across the 10, 12, and 13 panel configurations as well.

Buying 6 Panel Oral Swab Drug Tests in Bulk

At 12 Panel Now, both configurations of the 6 panel saliva drug test are available at wholesale pricing starting from $1.39 per unit with same-day shipping on orders placed before 3:00 PM EST and free shipping on qualifying orders. Confirm the correct configuration before placing a bulk order. The ALC and BZO configurations serve entirely different program populations and cannot be substituted for each other once an order is placed. Store all kits between 36°F and 86°F away from direct sunlight and humidity. The alcohol analyte in the ALC configuration is particularly sensitive to heat exposure and should not be stored in environments where temperatures regularly exceed 86°F. We carry over 15 million products in stock across our US-based warehouse at all times with no backorders, no supply gaps, and no fulfillment delays between testing cycles. Send us a competitor rate sheet and we beat it by 10% guaranteed. OEM, private label, and custom configuration orders are available. Contact the wholesale team at 561-897-9238 or [email protected].

This page covers the 6 Panel Oral Swab Drug Test category at 12 Panel Now, located at 12panelnow.com/product-category/oral-swabs/6-panel-oral-swab/. The two available configurations are: ALC variant covering AMP/COC/MET/OPI/OXY/ALC and BZO variant covering AMP/BZO/COC/MET/OPI/OXY. All products carry a Forensic Use Only classification and are available for same-day wholesale shipping from the 12 Panel Now US-based warehouse at 801 N Congress Ave, Boynton Beach FL 33426. Regulatory references: SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid, effective October 10, 2023. SAMHSA addition of fentanyl to the Authorized Drug Testing Panel, effective July 7, 2025. DOT authorization of oral fluid testing under 49 CFR Part 40, final rule published May 2, 2023.

Cutoff levels align with SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs using Oral Fluid, effective October 10, 2023. Detection windows are approximate and vary based on dosage, frequency of use, and individual metabolism. All results at or above the stated cutoff concentration are presumptive positive and require laboratory confirmation using GC-MS or LC-MS/MS before any consequential action is taken.